ArticleUrologic oncology2018
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.
Article in Urologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.Prostate cancer and prostatic diseases · 2019Pooled it
- Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.Future oncology (London, England) · 2026Article
- Article
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Risk of reclassification and novel tools in active surveillance.Asian journal of urology · 2025Review
- Article
- Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.International journal of molecular sciences · 2025Review
- Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.Prostate cancer and prostatic diseases · 2025Observational
- Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.JCO precision oncology · 2024Article
- Association between urology practice use of multiparametric MRI and genomic testing and treatment of men with newly diagnosed prostate cancer.Urologic oncology · 2023Article
- Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing.BJUI compass · 2022Article
- Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.Cancer reports (Hoboken, N.J.) · 2022Article
- Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy.Cancers · 2021Article
- Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.Journal of personalized medicine · 2021Review
- Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice.International journal of molecular sciences · 2021Review
- Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.The Prostate · 2021Article
- Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.Personalized medicine · 2019Article
- Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer.JCO precision oncology · 2018Article
- Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundA combined clinical cell-cycle risk (CCR) score that incorporates prognostic molecular and clinical information has been recently developed and validated to improve prostate cancer mortality (PCM) risk stratification over clinical features alone. As clinical features are currently used to select men for active surveillance (AS), we developed and validated a CCR score threshold to improve the identification of men with low-risk disease who are appropriate for AS.
methodsThe score threshold was selected based on the 90th percentile of CCR scores among men who might typically be considered for AS based on NCCN low/favorable-intermediate risk criteria (CCR = 0.8). The threshold was validated using 10-year PCM in an unselected, conservatively managed cohort and in the subset of the same cohort after excluding men with high-risk features. The clinical effect was evaluated in a contemporary clinical cohort.
resultsIn the unselected validation cohort, men with CCR scores below the threshold had a predicted mean 10-year PCM of 2.7%, and the threshold significantly dichotomized low- and high-risk disease (P = 1.2 × 10
conclusionsThe CCR score threshold appropriately dichotomized patients into low- and high-risk groups for 10-year PCM, and may enable more appropriate selection of patients for AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.